All Posts Tagged With: "THRX"
(THRX) Theravance Third Quarter Loss Deteriorates
Theravance Inc.’s (THRX) third quarter 2011 loss per share of 37 cents was wider than the Zacks Consensus loss Estimate of 33 cents as well as the year-ago loss of 29 cents per share. The wider loss was...
(THRX) Theravance Analyst Maintains Neutral on Shares
We have maintained our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $24.00 per share following the announcement of first quarter 2011 financial results.
Theravance’s first...
(THRX) Theravance Analyst Maintains Neutral Rating on Shares
We have maintained our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $24.00 per share following the announcement of first quarter 2011 financial results.
Theravance’s first...
(THRX) Theravance Reports Earnings In Line With Estimates
Theravance Inc.’s (THRX) first quarter 2011 loss per share of 28 cents was in line with the Zacks Consensus Estimate but narrower than the year-ago loss of 35 cents per share. Earnings improvement was driven...
(THRX) Theravance Analyst Maintains Neutral on Shares
We are maintaining our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $25.00 after the company’s fourth quarter and fiscal year 2010 financial results.
Theravance’s...
(THRX) Theravance Third Quarter 2010 Earnings Loss Wider Than Expected
Theravance Inc.’s (THRX) third quarter 2010 loss per share of $0.29 was $0.02 wider than the Zacks Consensus Estimate, but narrower than the year-ago quarter loss of $0.35.
Revenue at Theravance...
(THRX) Theravance Reports Wider Loss Than Forecast
Theravance (THRX) reported first quarter fiscal 2010 loss per share of 35 cents, 7 cents more than the Zacks Consensus Estimate and worse than the loss of 29 cents in the year-ago period.
Theravance...
(THRX) Theravance Begins Phase II Mid-stage Trial
Theravance (THRX) began a phase II “proof of concept” clinical trial for one of its pipeline candidates, TD-1211. The drug, an orally-administered peripherally selective mu opioid receptor antagonist...
(THRX) Theravance Offers 7.5 Million Shares
Theravance (THRX) has decided to raise funds by offering 7.5 million shares. Net proceeds are expected to be utilized for general corporate purposes including research expenses and debt reduction. However,...
(THRX) Theravance’s Earnings Report Misses Estimates
During the fourth quarter of 2009, Theravance’s (THRX) loss per share came in at 35 cents, missing the Zacks Consensus Estimate by two cents and worse than the loss of 26 cents reported in the year-ago...
(JNJ) Johnson and Johnson Suffers Another Pipeline Setback
Johnson and Johnson (JNJ) has received yet another setback related to its pipeline candidate ceftobiprole, a broad-spectrum antibiotic ? aiming the methicillin-resistant Staphylococcus aureus (MRSA)...
(THRX) Theravance Gets Major Setback From FDA
Theravance (THRX) received a major setback in the approval process of Vibativ (telavancin) for the treatment of nosocomial pneumonia (NP). Recently, the company received a complete response letter (CRL) regarding...
(THRX) Theravance Earnings Post Loss Wider Than Expected
Theravance (THRX) announced its third quarter results after the closing bell yesterday. The company’s loss per share came in at 35 cents, a penny wider than the Zacks Consensus Estimate. It had earned 34...
(THRX) Theravance Earns Milestone Payment
Recently, Theravance (THRX) received a milestone payment of $20 million from its partner Astellas Pharma. The payment follows the U.S. Food and Drug Administration (FDA) approval of Vibativ (telavancin) and...
(THRX) Theravance Earns FDA Approval for Skin Infection Drug
In a quantum achievement, Theravance (THRX) received approval from the US Food and Drug Administration (FDA) to market its Vibativ (telavancin) for complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria.
Vibativ,...
(FRX) Forest Laboratories Presents Encouraging Data
We are pleased to hear that Forest Laboratories (FRX) presented encouraging data from its phase III trial of ceftaroline for the treatment of community-acquired pneumonia [CAP] in hospitalized patients. The company presented new data from two multicenter studies...
(JNJ) Johnson & Johnson Responds to FDA Questions on Antibiotic Drug Trials
We are pleased to hear that the US Food and Drug Administration (FDA) has accepted Johnson & Johnson’s (JNJ) response on clinical trial-related issues. Last month, the agency had warned the company for not maintaining proper records during the trial...